Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
• * Stage IIIA or IIIB disease
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan
• No clinically significant malignant pleural or pericardial effusion (i.e., stage IIIB wet disease)
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Absolute neutrophil count \> 1,500/mm³
• Platelet count \> 100,000/mm³
• Hemoglobin ≥ 8.0 g/dL
• Bilirubin normal
• Alkaline phosphatase (AP), AST, and ALT meeting 1 of the following criteria:
• * AP normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)
• * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
• * AP ≤ 5 times ULN AND AST or ALT normal
• Creatinine \< 2.0 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
• No New York Heart Association class III-IV heart disease
• No history of serious cardiac disease not adequately controlled
• No documented myocardial infarction within the past 6 months
• No congestive heart failure
• No unstable angina
• No clinically significant arrhythmia
• No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
• No peripheral neuropathy \> grade 1
• No other malignancy within the past 5 years other than skin cancer
• PRIOR CONCURRENT THERAPY:
• More than 3 weeks since prior major surgery
• No prior systemic chemotherapy, thoracic radiotherapy, or surgical resection for NSCLC